BioSpace News Archive

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2020, after the market close on February 25, 2021.

Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, announced the publication of new clinical data in the International Journal of Cardiology.

Acadia Pharmaceuticals Inc. announced that it will participate at the following investor conferences

Findings of study published in PLOS One found a highly significant correlation between temperature and the rate of increase in COVID-19

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on February 24, 2021, to discuss its fourth quarter 2020 results and provide a business update

The American Gastroenterological Association (AGA) has officially endorsed a novel Clinical Decision Support Tool (CDST) designed for healthcare providers managing patients with IBD who need evidence-based guidance on biologic therapy selection.

Battelle , the world’s largest independent private R&D organization, announced today that it is in discussions to provide Cascade Environmental with a patented process (International Patent US10,907,143 B2) for the use of encapsulated enzymes to remediate recalcitrant pollutants.

The new four-part program promotes cleanliness, confidence and compliance allowing facilities to reopen - and stay open - with peace of mind

Woolsey Pharmaceuticals, a clinical-stage company developing treatments for neurodegenerative diseases, today announced dosing of the first patient with BRAVYL in its FOUND (Fasudil fOr Uncontrolled waNDering) study for Alzheimer’s and Vascular Dementia patients who have wandering behaviors of elopement and/or getting lost.

Fresenius Kabi Canada, a health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today it has introduced IDACIO®, an adalimumab biosimilar, in Canada.